Beste Öztürk

Beste Öztürk

Auto-generated profile, based on publicly available information

Beste Öztürk


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Intercontinental Journal of Emergency Medicine
Verified
Journal Article
Open access
PDF file
ZZZengin Zengin
Zengin Zengin
OOOguz Ozturk
Oguz Ozturk
HCHuseyin Camli
Huseyin Camli
BÖBeste Öztürk
Beste Öztürk
BGBerk Güvercin
Berk Güvercin
IAIhsan Ates
Ihsan Ates
Aims: The aim of this study was to investigate the relationship between fibroblast growth factor 21 (FGF-21) levels and coronary artery calcium (CAC) scores calculated using the Agatston method, and to evaluate the potential of FGF-21 as a non-invasive biomarker for the assessment of coronary artery calcification. Methods: A total of 54 adult individuals who had undergone coronary CT angiography within the past three months solely for cardiovascular risk assessment were prospectively included in the study. Serum FGF-21 levels were measured using the ELISA method, and CAC scores were determined via the Agatston scoring system. The relationship between FGF-21 levels and CAC scores was analyzed using Spearman’s correlation test. Results: A significant and strong positive correlation was observed between FGF-21 levels and CAC scores (r = 0.725, p < 0.001). Diabetes mellitus and hyperlipidemia were significantly associated with higher CAC scores (p = 0.006 and p = 0.024, respectively), whereas their associations with FGF-21 levels were not statistically significant (p = 0.065 and p = 0.104). No significant correlations were found between FGF-21 levels and other variables such as age, gender, hypertension, or biochemical parameters. Conclusion: The findings suggest that serum FGF-21 levels may be associated with coronary artery calcification and could serve as a non-invasive and easily applicable biomarker in individuals for coronary artery disease. FGF-21 may be particularly useful in clinical settings where access to advanced imaging modalities is limited.